Differential expression of solute carrier family 29 member 4 in cancers of the breast.

Shahan Mamoor, MS¹

¹shahanmamoor@gmail.com

East Islip, NY 11730

Breast cancer affects women at relatively high frequency¹. We mined published microarray datasets^{2,3} to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding solute carrier family 29 member 4, SLC29A4, when comparing primary tumors of the breast to the tissue of origin, the normal breast. SLC29A4 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of SLC29A4 in primary tumors of the breast was correlated with overall survival in patients with luminal B subtype cancer and in patients with normal-like subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. SLC29A4 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

Keywords: breast cancer, SLC29A4, solute carrier family 29 member 4, systems biology of breast cancer, targeted therapeutics in breast cancer.

Invasive breast cancer is diagnosed in over a quarter of a million women in the United States each year¹ and in 2018, breast cancer was the leading cause of cancer death in women worldwide⁴. While patients with localized breast cancer are provided a 99% 5-year survival rate, patients with regional breast cancer, cancer that has spread to lymph nodes or nearby structures, are provided an 86% 5-year survival rate^{5,6}. Patients with metastasis to distant sites, like the brain, are provided a 27% 5-year survival rate^{5,6}. Understanding how primary tumors are most transcriptionally different from the tissue from which they originate, the breast, can facilitate development of novel diagnostic and therapeutics to promote early detection and enhanced treatment, and contribute to efforts to prevent progression to metastatic stages. We mined published microarray data^{2,3} to understand at the transcriptome level and in an unbiased fashion genes most differentially expressed in primary tumors of the breast as compared to normal breast tissue. solute carrier family 29 member 4 emerged as among the most differentially expressed genes in cancer of the female breast.

Methods

We utilized datasets GSE42568² and GSE10893³ for this global differential gene expression analysis of female breast cancer. GSE42568 was generated using Affymetrix Human Genome U133 Plus 2.0 array technology with $n=17$ normal breast tissue biopsies and $n=104$ primary breast tumor biopsies from patients with breast cancer; analysis was performed using platform GPL570; the majority of patients whose tumors were analyzed were age 50 or older. GSE10893 was generated using Agilent-011521 Human 1A Microarray G4110A technology with $n=11$ primary breast tumors and $n=3$ brain metastases from patients with breast cancer; analysis was performed using platform GPL885. The Benjamini and Hochberg method of p -value adjustment was used for ranking of differential expression but raw p -values were used to assess statistical significance of global differential expression. Log-transformation of data was auto-detected, and the NCBI generated category of platform annotation was used. A statistical test was performed to evaluate whether SLC29A4 expression was significantly different between primary breast tumors and normal breast tissue using a two-tailed t-test. For Kaplan-Meier survival analysis, we used the Kaplan-Meier plotter online tool⁷ for correlation of SLC29A4 mRNA expression levels with overall survival (OS) in $n=296$ patients with basal-like subtype cancer, $n=222$ patients with luminal A subtype cancer, $n=200$ patients with luminal B subtype cancer, $n=198$ patients with HER2+ cancer, and $n=27$ patients with normal-like subtype cancer.

Results

We performed discovery of genes associated with breast cancer in females by mining two independently published microarray datasets^{2,3}.

SLC29A4 is differentially expressed in primary tumors of the breast.

Studying the global gene expression profiles of 104 breast cancers from patients aged 31 to 89 revealed that the gene encoding solute carrier family 29 member 4, SLC29A4, was among the genes most differentially expressed in tumors of the breast in human breast cancer (Chart 1). When sorting each of the genes expressed in tumors of the breast based on significance of difference as compared to normal breast tissue, SLC29A4 ranked 176 out of 54675 total transcripts, equating to 99.7% differential expression (Chart 1). Differential expression of SLC29A4 in female breast cancer was statistically significant (Chart 1; $p=1.79E-27$).

We looked to validate our findings using a second microarray dataset³, here comparing global gene expression patterns of 11 primary tumors of the breast and 3 brain metastases, revealing significant differential expression of SLC29A4 in human breast cancer (Chart 2). When sorting each of the genes

expressed in the tumors of patients with breast cancer based on significance of difference as compared to brain metastatic tissues, SLC29A4 ranked 4253 out of 17581 total transcripts, equating to 75.8% differential expression (Chart 2). Differential expression of SLC29A4 in brain metastatic breast cancer was statistically significant (Chart 2; $p=1.63E-04$). These data suggested that differential expression of SLC29A4 was not an artifact of a single microarray dataset, nor was it strictly associated with primary tumors of the breast, rather a general transcriptional feature of human breast cancer that reflects a spectrum of transformation.

SLC29A4 is expressed at significantly lower levels in breast tumors as compared to the breast.

We obtained exact mRNA expression levels for SLC29A4 from the breast and from breast tumors to understand the magnitude and direction of SLC29A4 expression change. SLC29A4 was expressed at lower levels in tumors of the breast as compared to normal breast tissue (Figure 1). Decreased expression of SLC29A4 in primary breast tumors was statistically significant (Figure 1: $p<0.0001$). SLC29A4 was expressed at 5.42 ± 1.73 arbitrary units (AU) in normal breast tissue, while it was expressed at 2.62 ± 0.45 AU in tumors of the breast. We calculated a mean fold change of 0.48 in SLC29A4 mRNA levels when comparing primary tumors of the breast to normal breast tissues.

SLC29A4 expression correlates with survival outcomes in luminal B and normal-like subtype human breast cancer.

We performed Kaplan-Meier survival analysis to study relationships between tumor SLC29A4 mRNA expression levels and survival outcomes in patients with breast cancer. We observed a correlation between SLC29A4 expression and overall survival (OS) in patients with luminal B subtype breast cancer which trended towards statistical significance (Figure 2; log rank p -value: 0.039 for overall survival, hazard ratio: 1.81 (1.02-3.21) (Fig. 2)). SLC29A4 mRNA levels were a negative prognostic indicator in luminal B subtype breast cancer patients. Median OS was 135.84 months for luminal B patients with low tumor expression of SLC29A4 while median OS was 66 months for luminal B patients with high tumor expression of SLC29A4 (Chart 3).

We observed a correlation between SLC29A4 expression and overall survival (OS) in patients with normal-like subtype breast cancer which trended towards statistical significance (Figure 2; log rank p -value: 0.077 for overall survival, hazard ratio: 3.43 (0.81-14.44) (Fig. 2)). SLC29A4 mRNA levels were a negative prognostic indicator in normal-like subtype breast cancer patients. Median OS was 78 months for normal-like patients with low tumor expression of SLC29A4 while median OS was 36 months for normal-like patients with high tumor expression of SLC29A4 (Chart 3).

SLC29A4 primary tumor expression was not correlated with overall survival in basal-like breast cancer (Figure 2; log rank p -value: 0.99 for OS, hazard ratio: 1 (0.63-1.6) (Fig. 2)), luminal A subtype breast cancer (Figure 2; log rank p -value: 0.31 for OS, hazard ratio: 1.44 (0.71-2.92) (Fig. 2)), or in patients with HER2+ breast cancer (Figure 2; log rank p -value: 0.17 for OS, hazard ratio: 1.46 (0.85-2.52) (Fig. 2)).

Thus, through comparative transcriptome analysis of primary tumors of the breast and normal breast tissue, we found that differential expression and down-regulation of SLC29A4 was among the most significant transcriptional features in primary tumors from patients with breast cancer. SLC29A4 expression in primary tumors of the breast was correlated with overall survival in patients with luminal B and normal-like subtype disease, with mRNA levels of SLC29A4 a negative prognostic indicator for both luminal B and normal-like breast cancer patients.

Discussion

Invasive breast cancer is a medical problem with a 27% 5-year survival rate for women whose disease has spread to distant sites^{5,6}. To facilitate understanding of the basic transcriptional differences between primary tumors of the breast and the tissues from which these tumors originate, normal breast tissues, we performed comparative transcriptome analysis using two independently published microarray datasets^{2,3}, providing evidence here that differential expression of solute carrier family 29 member 4, encoded by SLC29A4, is a defining transcriptional feature of human breast cancer: in patients diagnosed after age 50, and in the brain metastases of patients with metastatic breast cancer. SLC29A4 was expressed at significantly lower levels in primary tumors from patients with breast cancer as compared to normal breast tissue. Importantly, in patients with luminal B and normal-like subtype breast cancers, expression of SLC29A4 was correlated with overall survival. Solute carrier family 29 member 4 and the molecular processes to which it pertains to may be relevant to the initiation or progression of human breast cancer.

References

1. DeSantis, C.E., Ma, J., Goding Sauer, A., Newman, L.A. and Jemal, A., 2017. Breast cancer statistics, 2017, racial disparity in mortality by state. *CA: a cancer journal for clinicians*, 67(6), pp.439-448.
2. Clarke, C., Madden, S.F., Doolan, P., Aherne, S.T., Joyce, H., O'driscoll, L., Gallagher, W.M., Hennessy, B.T., Moriarty, M., Crown, J. and Kennedy, S., 2013. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. *Carcinogenesis*, 34(10), pp.2300-2308.
3. Weigman, V.J., Chao, H.H., Shabalin, A.A., He, X., Parker, J.S., Nordgard, S.H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A. and Kristensen, V.N., 2012. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. *Breast cancer research and treatment*, 133(3), pp.865-880.
4. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 68(6), pp.394-424.
5. ACS Cancer Facts & Figures 2019.
<https://www.cancer.net/cancer-types/breast-cancer/metastatic/statistics>.
6. Survival Rates for Breast Cancer. <https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html>
7. Györfy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q. and Szallasi, Z., 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast cancer research and treatment*, 123(3), pp.725-731.

Rank: 176
Probe ID: 227281_at
p-value: 1.79E-27
t: 1.42E+01
B: 51.9356875
Gene: SLC29A4
Gene name: solute carrier family 29 member 4

Chart 1: SLC29A4 is differentially expressed in the primary tumors of patients with breast cancer.

Rank of differential expression, probe ID, p-value of global differential expression, t, a moderated t-statistic, B, the log-odds of differential expression between the groups compared, gene and gene name are listed in this chart.

Rank: 4253
Probe ID: 2988594
p-value: 1.63E-04
t: 4.07
B: 0.258979
Gene: SLC29A4
Gene name: solute carrier family 29 member 4

Chart 2: SLC29A4 is differentially expressed in brain metastasis tissues of patients with metastatic breast cancer when compared to primary tumors of the breast.

Rank of differential expression, probe ID, p-value of global differential expression, t, a moderated t-statistic, B, the log-odds of differential expression between the groups compared, gene and gene name are listed in this chart.

Figure 1: SLC29A4 is expressed at significantly lower levels in primary breast tumors as compared to normal breast tissue.

The mRNA expression level of SLC29A4 in normal breast tissue (left) and in primary tumors of the breast (right) is graphically depicted with the result of a statistical test evaluating significance of difference in SLC29A4 expression between normal breast tissue and primary tumors of the breast, a *p*-value, listed above.

Figure 2: SLC29A4 expression correlates with overall survival in patients with luminal B subtype breast cancer and in patients with normal-like breast cancer, but not in patients with basal, luminal A, or HER2+ subtype cancer.

Depicted in this Kaplan-Meier plot is the probability of overall survival (OS) for $n=296$ patients with basal-like breast cancer (upper left), $n=198$ patients with HER2+ breast cancer (upper right), $n=222$ patients with luminal A breast cancer (middle left), $n=200$ patients with luminal B breast cancer (middle right), and $n=27$ patients with normal-like breast cancer (below) stratified into two groups, based on low or high

expression of SLC29A4 in patient primary tumors. The log rank p-value denoting statistical significance of difference in overall survival when comparing the two groups, as well as hazard ratio for this comparison is listed above. Listed below is the number of patients at risk (number of patients alive) per interval, after stratification based on SLC29A4 expression; in the first interval, number at risk is number of patients alive; in each subsequent interval, number at risk is the number at risk less those who have expired or are censored.

Luminal B patients

Low SLC29A4 expression: 135.84 months

High SLC29A4 expression: 66 months

Normal-like patients

Low SLC29A4 expression: 78 months

High SLC29A4 expression: 36 months

Chart 3: In luminal B and normal-like subtype breast cancer, median overall survival is superior in patients with low primary tumor expression of SLC29A4.

The overall survival of $n=200$ luminal B subtype breast cancer patients and $n=27$ normal-like subtype breast cancer patients based on stratification into low or high tumor expression of SLC29A4 is listed in this chart.